Johnson & Johnson vs Reckitt

10-Q Financial Filing Analysis for Johnson & Johnson (2026-10-21)

Johnson & Johnson reported fiscal Q3 2026 sales to customers of $25.40 billion, up 5.9% year-over-year (6.0% operational growth), driven by double-digit growth in Oncology and steady demand in MedTech, which offset biosimilar erosion from STELARA. However, consolidated net earnings collapsed to $210 million (diluted EPS of $0.09) from $5.15 billion in Q3 2025. This sharp profitability decline was primarily caused by a $5.5 billion pre-tax accrual recorded in Other (income) expense, net for a proposed comprehensive settlement of the talc ovarian cancer litigation, alongside a $1.0 billion in-process R&D charge from the Firefly Bio acquisition and ongoing Orthopaedics separation costs.

• Worldwide sales reached $25.40 billion in Q3 2026 (+5.9% YoY) and $74.77 billion for the first nine months (+7.4% YoY), supported by gains in DARZALEX ($4.24 billion in Q3) and TREMFYA ($2.40 billion in Q3).
• Net earnings plummeted to $210 million in Q3 2026 due to a $5.5 billion litigation charge to resolve ovarian talc claims and a $1.0 billion acquired IPR&D charge for Firefly Bio, Inc.
• Total present value of reserves for talc-related legal matters reached approximately $9.0 billion as of September 27, 2026, while the planned separation of the Orthopaedics business remains on track for mid-2027.

Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

Revolutionary IL-23R targeted oral peptide delivers sustained skin clearance and a favorable safety profile in patients with psoriasis affecting sensitive, highly visible areas of the body. 60% of patients with scalp psoriasis and 89% with genital psoriasis achieved site-specific complete skin clearance at Week 112.

A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma

Johnson & Johnson published a behind-the-scenes feature on September 25, 2026, highlighting how the company manufactures and delivers CAR-T cell therapy for multiple myeloma. The article focuses on the complexity of producing and distributing this personalized cancer treatment. No specific clinical data, product names, or commercial terms are disclosed in the provided text.

• Johnson & Johnson published a behind-the-scenes feature on September 25, 2026.
• The article focuses on Johnson & Johnson's CAR-T cell therapy manufacturing and delivery for multiple myeloma.
• The provided article text does not reveal specific product names, trial results, or financial terms.

Durex Signs Sean Dyche for 'Get Wood Rising' Campaign

Durex, a brand by Reckitt, has launched a season-long comedy campaign called 'Get Wood Rising' with former Premier League manager Sean Dyche as 'performance director.' The campaign, created by McCann Content Studios at McCann London, centers on a fictional partnership with real non-league club Woodley United FC, which hasn't had a promotion in 10 years. The 100-second launch film uses innuendo and humor to promote Durex Performance condoms and gel, featuring comedian Chris McClure as a performance assistant. The social-first campaign debuted on October 9, 2026, and amassed over a million views on Instagram within hours. Documentary-style episodes and behind-the-scenes content will run across Meta, TikTok, and influencer channels throughout the season. The campaign aims to make conversations about sexual performance more open and relatable while driving brand awareness and market share.

• Durex launched 'Get Wood Rising', a season-long campaign with former Premier League manager Sean Dyche.
• The campaign is a partnership with non-league football club Woodley United FC.
• The launch film gained over one million views on Instagram within hours of its October 9 launch.

Putting Better Health in More Hands: Reckitt Pakistan Unveils Saaf Sehatmand Pakistan in Partnership with Aga Khan Foundation

Reckitt Pakistan has unveiled the Saaf Sehatmand Pakistan initiative in partnership with the Aga Khan Foundation. The initiative aligns with Reckitt's mission to improve health and hygiene access across communities. Further operational specifics were not detailed in the published release snippet.

• Reckitt Pakistan announced the Saaf Sehatmand Pakistan health initiative.
• The initiative is launched in partnership with the Aga Khan Foundation.
• The program aligns with Reckitt's corporate purpose of delivering better health into more hands.

Veet, Gocomo Launch 'The Smooth Switch' Creator Campaign

Veet has launched a summer creator campaign called "The Smooth Switch" in collaboration with Berlin-based social-first agency Gocomo. The campaign addresses hair removal with a humorous and deliberately imperfect tone and aims to generate buzz through the participation of eight creators. The article notes this is the first direct collaboration between the brand and the agency and references Gocomo's work with other Reckitt-owned brands such as Durex.

• Veet launched a summer creator campaign named "The Smooth Switch".
• The campaign was developed with Berlin social-first agency Gocomo.
• The campaign adopts a humorous, intentionally imperfect approach to hair removal.